WHO ICTRP trial
The effect of Tirzepatide once weekly on the morbidity and mortality of adults…
CTRI/2023/04/051445 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2023/04/051445 |
|---|---|
| Public title | The effect of Tirzepatide once weekly on the morbidity and mortality of adults living with obesity. |
| Scientific title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity |
| Primary sponsor | Eli Lilly and Company India Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Mexico;Netherlands;Poland;Republic of… |
| Conditions | Health Condition 1: E669- Obesity, unspecified |
| Interventions | Intervention1: Tirzepatide: 2.5 mg Tirzepatide injected subcutaneously once weekly. The dose will increase 2.5 mg every 4 weeks until 15 mg. The study will last about 5 years. Control Intervention1: Placebo: 2.5 mg placebo injected… |
| Registration date | Oct 4, 2023 |
| Target size | 15000 |
| Secondary IDs | I8F-MC-GPIJ dated 14 Jun 2022;NCT05556512 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: